Cargando…

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine

Detalles Bibliográficos
Autores principales:	Trimboli, Michele, Zoleo, Pio, Arabia, Gennarina, Gambardella, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331323/ https://www.ncbi.nlm.nih.gov/pubmed/34346014 http://dx.doi.org/10.1007/s10072-021-05523-5

Ejemplares similares

Guillain–Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea
por: Kim, Namkyun, et al.
Publicado: (2022)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases
por: Bouattour, Nadia, et al.
Publicado: (2021)

Spinal cord ischemia complicating BNT162b2 mRNA COVID-19 vaccination
por: Fotiadou, Aggeliki, et al.
Publicado: (2022)

COVID-19-associated Guillain-Barré syndrome in the early pandemic experience in Lombardia (Italy)
por: Martinelli-Boneschi, Filippo, et al.
Publicado: (2022)

Guillain-Barré syndrome associated with COVID-19: an atypical, late-onset presentation
por: Fletman, Elizabeth W., et al.
Publicado: (2021)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome
por: Gigli, Gian Luigi, et al.
Publicado: (2020)

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
por: Tanzilli, Antonio, et al.
Publicado: (2022)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2
por: Umezawa, Shu, et al.
Publicado: (2022)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis following third dose of BNT162b2 COVID-19 vaccine in a patient with systemic lupus erythematosus
por: Kang, Minsung, et al.
Publicado: (2023)

Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021)

Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital
por: Ottaviani, Donatella, et al.
Publicado: (2020)

New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases
por: Assini, Andrea, et al.
Publicado: (2020)

COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications
por: Kajumba, Mayanja M., et al.
Publicado: (2020)

Facemask headache: a new nosographic entity among healthcare providers in COVID-19 era
por: Rapisarda, Laura, et al.
Publicado: (2021)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Case report of Guillain-Barré Syndrome after COVID BNT162b2 mRNA vaccine()
por: Sosa-Hernández, Oscar, et al.
Publicado: (2022)

Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine
por: García-Grimshaw, Miguel, et al.
Publicado: (2021)

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
por: Kang, Yu Min, et al.
Publicado: (2021)

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
por: Haji, Alhan, et al.
Publicado: (2023)

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
por: Iannone, Michela, et al.
Publicado: (2021)

Miller Fisher syndrome following Pfizer COVID-19 vaccine
por: Abičić, Ana, et al.
Publicado: (2021)

Syndrome de Guillain-Barré et COVID-19 : case report
por: Diaz, P., et al.
Publicado: (2020)

Herpes zoster and alopecia areata following mRNA BNT162b2 COVID‐19 vaccine: Controversial immune effects
por: Martora, Fabrizio, et al.
Publicado: (2022)

Spectrum of neurological complications following COVID-19 vaccination
por: Garg, Ravindra Kumar, et al.
Publicado: (2021)

Adverse Events Following COVISHIELD Vaccination Among Adult Population in Bangladesh
por: Khalil, Md. Musab, et al.
Publicado: (2021)

A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2
por: Schroeder, Jan Walter, et al.
Publicado: (2022)

Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination
por: Tomayko, Mary M., et al.
Publicado: (2021)

Bell’s palsy following COVID-19 vaccination with high CSF antibody response
por: Obermann, Mark, et al.
Publicado: (2021)

A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine
por: Ryu, Dong-Woo, et al.
Publicado: (2021)

Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects
por: Pham, Michele N., et al.
Publicado: (2022)

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
por: Kwon, Hyeryung, et al.
Publicado: (2021)

A case of anti-MOG antibody-positive ADEM following COVID-19 mRNA vaccination
por: Miyamoto, Katsuichi, et al.
Publicado: (2022)

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination
por: Riise, Jon, et al.
Publicado: (2022)

Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge
por: D’Apolito, Maria, et al.
Publicado: (2023)

Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
por: Tapdia, Madhusudan, et al.
Publicado: (2022)

Case of Guillain-Barré syndrome following COVID-19 vaccine
por: Hasan, Tanveer, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l0k0mv352lu78dg4eo484t48cm